HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

In a cohort of 300 patients with HER2+ breast cancer, results of the TROIKA study demonstrate that random assignment of either HD201 or referent trastuzumab combined with standard chemotherapy over a duration of 12 weeks leads to no statistical efficacy differences.

Access the full article to read more here.